
Gilead Advances HIV Prevention in Low-Income Countries Amid Funding Concerns
Gilead Sciences plans to supply its HIV prevention injection lenacapavir to low-income countries if approved by the FDA, despite funding uncertainties due to U.S. aid cuts, with potential rollout in 2026 to help end the HIV epidemic globally.
